



Press release

SHL terminates ADR program

Tel Aviv / Zurich, 7 July 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that the Deposit Agreement, dated January 31, 2014, regarding the American Depositary Receipts (“ADRs”) among SHL Telemedicine, The Bank of New York Mellon, as Depositary, and owners and holders of American Depositary Receipts (the "Deposit Agreement") will be terminated. As a result, the existing ADR facility will be terminated effective at 5:00 PM (Eastern Time) on August 7, 2017.

Under the terms of the Deposit Agreement, all owners and beneficial owners of this ADR (symbol SMDCY) have until at least December 8, 2017 to decide if they would like to attempt to surrender the SHL ADRs for delivery of the underlying shares. If the owners and beneficial owners surrender ADRs for delivery of the underlying shares, they must pay a cable fee of USD 17.50, a cancellation fee of up to USD 0.05 per ADS surrendered and any applicable U.S. or local taxes or governmental charges. Payment should be made payable to The Bank of New York Mellon.

Subsequent to December 8, 2017, under the terms of the Deposit Agreement, the Depositary may attempt to sell the underlying shares. If the Depositary has sold such shares, owners and beneficial owners must surrender their ADRs to obtain payment of the sale proceeds, net of the expenses of sale, any applicable U.S. or local taxes or government charges and a cancellation fee of up to USD 0.05 per ADRs.

To surrender the ADRs, the address of the Depositary is: The Bank of New York Mellon, 101 Barclay Street, Depositary Receipts Division – 22nd Floor, Attention: Cancellation Desk, New York, NY 10286. Registered or overnight mail is the suggested method of delivering DRs to the Depositary.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.